



**KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LIMITED**  
**CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2023**

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-23	For the year ended 31-Mar-22
<b>A. Cash flow from operating activities</b>		
Net profit before tax	3425.40	3251.62
<b>Adjustments for non cash &amp; Non operating items:</b>		
Depreciation and amortization	757.19	813.95
Lease remeasurement Charges	37.29	0.00
Interest on Lease	20.88	25.38
Interest received from Banks	(212.41)	(219.98)
Interest expenses seperately considered	25.14	64.35
Interest Provision on Ankur Case	509.78	0.00
Excess provision reversed	(38.14)	(2.24)
Provision for Contingencies	0.00	178.31
Provision for Doubtful Debts	143.33	149.31
Provision made/(withdrawn)for slow moving/non moving inventory	29.92	12.59
Unrealised Foreign Exchange Loss (Gain)	(10.25)	(4.25)
Loss (Gain) from sale of Fixed Assets	(4.95)	2.40
Sundry Credit balances written back	(340.70)	(0.32)
<b>Operating profit before working capital changes:</b>	<b>4342.48</b>	<b>4271.12</b>
<i>Changes in working capital</i>		
Decrease / (Increase) in Inventories	947.74	(1954.14)
Decrease / (Increase) in Trade and Other Receivables	631.09	(7361.70)
(Decrease) / Increase in Trade Payables and Other Liabilities	55.55	3290.86
<b>Cash generated from operations</b>	<b>5,976.86</b>	<b>(1,753.86)</b>
Income taxes paid	(771.49)	(863.52)
<b>Net cash generated by operating activities</b>	<b>5,205.37</b>	<b>(2,617.38)</b>
<b>B. Cash flow from investing activities</b>		
Purchase of fixed assets, Capital WIP, Capital Advances	(2464.18)	(602.79)
Proceeds from Sale of PPE	9.17	39.53
Interest received from Banks	212.41	219.98
<b>Net cash from investing activities</b>	<b>(2242.60)</b>	<b>(343.28)</b>
<b>C. Cash flow from financing activities</b>		
Interest paid	(25.14)	(64.35)
Repayment of Long Term Borrowings	(75.00)	(300.00)
Increase/(Decrease) in short term Bonowings	(225.00)	0.68
Registration Charges for Leased Land	(350.15)	(2.59)
Payment of Lease Liabilities	(52.23)	(51.28)
Interest on Lease	(54.38)	(25.38)
Dividend paid on equity shares	(404.70)	(404.70)
<b>Net cash from financing activities</b>	<b>(1186.60)</b>	<b>(847.62)</b>
<b>D. Net changes in cash and cash equivalents (A + B + C)</b>	<b>1,776.17</b>	<b>(3,808.28)</b>
Cash and cash equivalents at the beginning of the year	4490.11	8298.39
Cash and cash equivalents at the end of the year	6266.28	4490.11
<b>Reconciliation of Cash and Cash equivalents with the Balance Sheet</b>		
Cash and Cash equivalents as per Balance Sheet	1,478.26	1,164.63
Add: Bank Balances not considered as Cash and Cash Equivalents as defined in IND AS 7 Cash Flow Statement	4,788.02	3,325.48
<b>Net Cash and Cash Equivalents</b>	<b>6,266.28</b>	<b>4,490.11</b>
<b>Cash and Cash equivalents at the end of the year Comprises (also refer note No 9 &amp; 10)</b>		
a) Cash on hand	0.34	0.50
b) In cash Credit	910.70	473.87
c) In fixed deposit account	4,987.47	3,890.16
d) In fixed deposit account-Margin Money	367.77	125.58
Significant Accounting Policies and accompanying Notes No. 1 to 50 form an Integral part of the Financial Statements		
This is the Cash Flow Statement referred to in Audit Report of even date For YOGANANDH & RAM LLP Chartered Accountants FRN: 005157S/S200052		
For and on behalf of Board of Directors of Karnataka Antibiotics and Pharmaceuticals Ltd CIN: U24291KA1981GOI004145		
	M Kar	
<b>Sunil Kumar Kaimal</b> Managing Director DIN: 08528098	<b>Dr. Madhuchanda Kar</b> Independent Director DIN :09519016	
<b>Manoj Kumar Jain</b> Partner Membership No 218610	<b>Supriya Kulkarni</b> Company Secretary Finance	
Date: 18th July 2023 Place: Bengaluru		

